Momcozy Survey Finds Moms Face Biggest Challenges of Time and Breast Pump Management, When Referring to Breastfeeding and Pumping Demands
23.2.2023 09:07:00 EET | Business Wire | Press release
In a recent survey, Momcozy, the best-selling wearable breast pump brand in North America found that moms struggle with breastfeeding and breast pumping mostly due to a lack of time, space, and the right breast pump. In addition, wearable breast pumps that allow moms to pump hands-free anywhere to balance life enjoyment and nursing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005522/en/
Momcozy Breastfeeding and Pumping Experience Survey results (Graphic: Business Wire)
The survey was conducted from July 25th, 2022- September 13th, 2022, via Momcozy’s social media accounts and newsletter targeting North American moms, and garnered nearly 1000 responses, which found:
- Moms face many hurdles to successful breastfeeding, including breast health issues, latching problems, and isolation sense. The most common difficulty however was managing the time to pump around busy schedules, along with the difficulties of breast pump management.
- Generally, moms with wireless, wearable pumps reported more positive pumping experiences compared with their traditional breast pump counterparts.
- Most respondents pump at home, at work, or in transit, indicating moms spend most of their time between taking care of their child, and earning income.
- In terms of the ‘craziest’ place moms ever breast pumped, the most mentioned locations included at meetings, the grocery store, parties, and restaurants. Other locations mentioned such as festivals, amusement parks and sports games indicate that for some moms, wearable breast pumps allow them greater flexibility and freedom to do things they like.
These findings suggest that every minute of breastfeeding and expressing moms counts. While expressing goals can still be difficult, wearable breast pumps allow moms to express comfortably anytime, anywhere with confidence and freedom. In short, mothers have little time to choose when and where to express for themselves. But with a hands-free, wearable breast pump, moms can feel more secure pumping anywhere without missing out on the fun of their lives.
The Momcozy S12 Pro Wearable Breast Pump was developed with the full understanding of mothers' feeding needs. It can be seamlessly integrated into the busy schedule of mothers, providing an efficient breastfeeding experience and long battery life support to meet the needs of breastfeeding in various scenarios.“Always put moms on top” is what Momcozy has been fulfilling. Through cozy designs born from love and continuous innovation, Momcozy brings a much simpler, more relaxed, and more comfortable experience for moms globally through their pregnancy and early motherhood.
About Momcozy
Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms, is the best companion for moms globally through their pregnancy and early motherhood. Centering around wearable breast pumps, Momcozy offers a wide range of products covering nursing, clothing and textile, FMCG, security, and more to accompany moms through their pregnancy and early motherhood in a more comfy and convenient way, making it the choice of Gen Z and millennial moms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005522/en/
Contact information
Marketing Dept.
Ella Zheng
1-855-322-1777(Mon.-Fri. 8:30am-12:00pm;1:00pm-5:30pm PST)
ella.zheng@momcozy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
